CenterBook Partners LP Takes $2.36 Million Position in Repligen Corporation $RGEN

CenterBook Partners LP bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 17,672 shares of the biotechnology company’s stock, valued at approximately $2,362,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGEN. Hantz Financial Services Inc. lifted its holdings in shares of Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after buying an additional 293 shares during the last quarter. CWM LLC raised its stake in Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares during the last quarter. Center for Financial Planning Inc. boosted its holdings in Repligen by 34.2% in the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 126 shares during the period. Trust Co. of Vermont acquired a new stake in Repligen in the 3rd quarter worth $67,000. Finally, Wilmington Savings Fund Society FSB increased its holdings in shares of Repligen by 2,750.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 495 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In related news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director directly owned 91,821 shares in the company, valued at $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by insiders.

Repligen Price Performance

Shares of RGEN stock opened at $137.22 on Friday. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $175.77. The stock has a market capitalization of $7.72 billion, a PE ratio of 6,864.43, a PEG ratio of 2.52 and a beta of 1.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The stock’s fifty day moving average is $157.24 and its 200-day moving average is $145.97.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Barclays increased their target price on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Wells Fargo & Company raised their price objective on Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group lifted their price objective on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. UBS Group boosted their price objective on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average price target of $177.92.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.